Integrilin eptifibatide: Phase IV data; marketed

CORR and partner Schering-Plough Corp. (SGP, Kenilworth, N.J.) reported follow-up data from their Phase IV ESPRIT study showing a 7.5 percent incidence of death or MI during the six months following ...